{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:ema:caprelsa:0:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Acaprelsa%3A0%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00203,
    "timestamp_received": "2026-10-16T23:26:27.352939+00:00Z",
    "timestamp_returned": "2026-10-16T23:26:27.354969+00:00Z",
    "trace_id": "6f1f05e4-5be8-4a8b-a961-fa34172e18c6"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:ema:caprelsa:0:0",
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2022-11-28:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2022-11-28",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:caprelsa",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Caprelsa (vandetanib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Sanofi B.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Caprelsa",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "vandetanib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2012-03-02",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-08-16",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:547",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C3879",
          "conceptType": "Disease",
          "name": "Medullary Thyroid Cancer",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:THME",
                "code": "THME",
                "name": "Medullary Thyroid Cancer",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Medullary+Thyroid+Cancer+%28THME%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C3879",
            "code": "C3879",
            "name": "Thyroid Gland Medullary Carcinoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3879"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C2737",
          "conceptType": "Therapy",
          "name": "Vandetanib",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:1098413",
                "code": "1098413",
                "name": "vandetanib",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1098413"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:40238052",
                "code": "40238052",
                "name": "vandetanib",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/40238052"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "RET inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C2737",
            "code": "C2737",
            "name": "Vandetanib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2737"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:18",
                "present": true,
                "subject": {
                  "id": "bmkr:18",
                  "type": "CategoricalVariant",
                  "name": "v::RET",
                  "constraints": [
                    {
                      "type": "AdjacencyConstraint",
                      "orderKnown": false,
                      "adjoinedElements": [
                        {
                          "id": "gene:hgnc:9967",
                          "conceptType": "Gene",
                          "name": "RET",
                          "primaryCoding": {
                            "id": "coding:hgnc:9967",
                            "code": "HGNC:9967",
                            "system": "https://genenames.org",
                            "iris": [
                              "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967"
                            ]
                          },
                          "mappings": [
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ensembl:ensg00000165731",
                                "code": "ENSG00000165731",
                                "system": "https://www.ensembl.org",
                                "iris": [
                                  "https://www.ensembl.org/id/ENSG00000165731"
                                ]
                              }
                            },
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ncbi:5979",
                                "code": "5979",
                                "system": "https://www.ncbi.nlm.nih.gov/gene",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/gene/5979"
                                ]
                              }
                            },
                            {
                              "relation": "relatedMatch",
                              "coding": {
                                "id": "coding:refseq:NM_020975.6",
                                "code": "NM_020975.6",
                                "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6"
                                ]
                              }
                            }
                          ]
                        },
                        {
                          "type": "UnspecifiedElement"
                        }
                      ]
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Gene fusion"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:ema:caprelsa:0",
            "type": "Indication",
            "description": "Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2024-10-20:0",
                "type": "Contribution",
                "description": "Adding EMA approvals for use to database",
                "date": "2024-10-20",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:ema:2022-11-28:0",
                "type": "Contribution",
                "description": "Indication received approval from the European Commission.",
                "date": "2022-11-28",
                "contributor": {
                  "id": "agent:org:ema",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "European Medicines Agency",
                  "description": "Regulatory agency that approves medicines for use in the European Union."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:ema:caprelsa",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Caprelsa (vandetanib) [product information]. EMA.",
                "title": null,
                "aliases": [],
                "description": "Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.",
                "urls": [
                  "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf",
                  "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:ema",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "European Medicines Agency",
                      "description": "Regulatory agency that approves medicines for use in the European Union."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Sanofi B.V.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Caprelsa",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "vandetanib",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2012-03-02",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2023-08-16",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}